Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02964481 · ClinicalTrials.gov registry record
Malignant Hyperthermia Registry and Genetic Testing
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- 64
- Enrollment target
NCT02964481: Clinical Trial study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02964481 is a clinical trial that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02964481 was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to to determine the penetrance of known and probable pathogenic variants in genes and the factors that contribute to penetrance in a population of children and adults in the United States exposed to Malignant Hyperthermia (MH) trigger agents.
Primary Outcome
MHS subjects and CHCT negative controls recruited from the North American MH Registry will have whole genome sequencing
Interventions
- GENETIC Whole exome sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-08-18 |
| Est. Completion | 2017-02-28 |
Why NCT02964481 stopped before completion
NCT02964481 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Whole exome sequencing is the first listed.
NCT02964481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02964481 about?
NCT02964481 is a clinical study titled "Malignant Hyperthermia Registry and Genetic Testing". The purpose of this study is to to determine the penetrance of known and probable pathogenic variants in genes and the factors that contribute to penetrance in a population of children and adults in the United States exposed to Malignant Hyperthermia (MH) trigger agents.
What is the current status of trial NCT02964481?
This trial is currently terminated. The enrollment target is 64 participants. The study started on 2015-08-18. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT02964481?
The interventions under investigation include: Whole exome sequencing (GENETIC).
Who is sponsoring clinical trial NCT02964481?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI